PRMT5 and neoplasm: MTAP-deficient tumor cells accumulate high levels of MTA leading to a reduced PRMT5 activity, which renders these cells more susceptible toward additional PRMT5 inhibition compared to MTAP-competent cells (8, 22, 41, 42).